Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates Zacks - Tue May 9, 2023

Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CUE : 1.5950 (-8.86%)
ARMP : 3.23 (-0.62%)
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates Zacks - Mon Nov 14, 2022

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LUMO : 2.45 (-7.20%)
CUE : 1.5950 (-8.86%)
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 3, 2022

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

DCPH : 14.90 (-1.00%)
CUE : 1.5950 (-8.86%)
Cue Biopharma Reports Second Quarter 2022 Financial Results Globe Newswire - Thu Aug 4, 2022

BOSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.5950 (-8.86%)
Cue Biopharma to Present at the Guggenheim I&I Spotlight Series Globe Newswire - Mon Jul 11, 2022

BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.5950 (-8.86%)
Cue Biopharma to Present at the Jefferies Healthcare Conference Globe Newswire - Wed Jun 1, 2022

BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.5950 (-8.86%)
Cue Biopharma to Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire - Thu May 26, 2022

BOSTON, May 26, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.5950 (-8.86%)
AbCellera Biologics Inc. (ABCL) Beats Q1 Earnings and Revenue Estimates Zacks - Tue May 10, 2022

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 14.89% and 22.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

ABCL : 4.18 (-3.69%)
CUE : 1.5950 (-8.86%)
Cue Biopharma Reports First Quarter 2022 Financial Results Globe Newswire - Tue May 10, 2022

BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...

CUE : 1.5950 (-8.86%)
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Lags Revenue Estimates Zacks - Fri May 6, 2022

Intercept (ICPT) delivered earnings and revenue surprises of 34.83% and 2.51%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ICPT : 19.00 (+0.21%)
CUE : 1.5950 (-8.86%)

Barchart Exclusives

3 Gold Stocks to Buy as Israel Weighs Iran Response Barchart - Mon Apr 15, 3:50PM CDT
With geopolitical tensions simmering after Iran's weekend missile launch on Israel, demand for gold stayed strong in Monday's session. For investors seeking safe-haven exposure to the asset, here are three gold stocks that analysts recommend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot